These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 1358575

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid.
    Sung C, Blaney SM, Cole DE, Balis FM, Dedrick RL.
    Cancer Res; 1994 Oct 01; 54(19):5118-22. PubMed ID: 7923128
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG.
    Cancer Res; 1993 Mar 01; 53(5):1032-6. PubMed ID: 8439950
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
    van Warmerdam LJ, Verweij J, Schellens JH, Rosing H, Davies BE, de Boer-Dennert M, Maes RA, Beijnen JH.
    Cancer Chemother Pharmacol; 1995 Mar 01; 35(3):237-45. PubMed ID: 7805183
    [Abstract] [Full Text] [Related]

  • 12. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
    Wall JG, Burris HA, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G.
    Anticancer Drugs; 1992 Aug 01; 3(4):337-45. PubMed ID: 1330081
    [Abstract] [Full Text] [Related]

  • 13. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
    Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH.
    J Clin Oncol; 1992 Apr 01; 10(4):647-56. PubMed ID: 1312588
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J.
    Semin Oncol; 1997 Feb 01; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
    Abbruzzese JL, Madden T, Sugarman SM, Ellis AL, Loughlin S, Hess KR, Newman RA, Zwelling LA, Raber MN.
    Clin Cancer Res; 1996 Sep 01; 2(9):1489-97. PubMed ID: 9816325
    [Abstract] [Full Text] [Related]

  • 17. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1999 Jan 01; 5(1):69-75. PubMed ID: 9918204
    [Abstract] [Full Text] [Related]

  • 18. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
    Loos WJ, Gelderblom H, Sparreboom A, Verweij J, de Jonge MJ.
    Clin Cancer Res; 2000 Jul 01; 6(7):2685-9. PubMed ID: 10914710
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.